LOS ANGELES

洛杉矶

,

，

April 27, 2026

2026年4月27日

/PRNewswire/ -- Nervonik, Inc., a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, today announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S.

/PRNewswire/ -- Nervonik, Inc.是一家开发下一代周围神经刺激（PNS）技术的临床阶段医疗器械公司，今天宣布完成了超额认购的5250万美元B轮融资。本轮融资由Amzak Health领投，美国Elevage Medical Technologies参与。

Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital..

美国风险伙伴（USVP）、鲁米拉风险投资、富特希尔风险投资和上湾资本。

The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities.

融资所得将支持Nervonik的PNS系统的持续开发和商业化，包括其专有传感能力的进一步开发。

'Nervonik is building a fundamentally differentiated neuromodulation platform that integrates stimulation with advanced sensing to deliver more precise and personalized therapy,' said Aydin Babakhani, CEO and Founder of Nervonik. 'This financing enables us to accelerate our clinical programs, prepare for commercialization, and bring a truly intelligent, next-generation therapy to the patients who need it most.'.

“Nervonik 正在构建一个根本上差异化的神经调节平台，该平台将刺激与先进传感技术相结合，以提供更精准和个性化的治疗，”Nervonik 首席执行官兼创始人阿伊丁·巴巴哈尼表示。“这笔融资使我们能够加速临床项目，为商业化做好准备，并为最需要的患者带来真正智能的下一代疗法。”

The company's technology incorporates real-time physiological feedback to enhance therapy personalization and efficacy. Early data demonstrate successful recording of evoked compound action potentials (ECAPs) and other biomarkers using implantable leads, positioning Nervonik at the forefront of next-generation bioelectronic medicine..

该公司技术结合了实时生理反馈，以提高治疗的个性化和效果。早期数据显示，使用可植入导线成功记录了诱发复合动作电位（ECAP）和其他生物标志物，使Nervonik处于下一代生物电子医学的前沿。

'Peripheral nerve stimulation is at an inflection point, with expanding clinical evidence and growing adoption in the treatment of chronic pain,' said Anthony Natale, MD, Partner at Amzak Health. 'Aydin and the Nervonik team have developed a highly differentiated technology platform that we believe has the potential to meaningfully improve the patient experience, and they are exceptionally well-positioned to capitalize on this opportunity.

“周围神经刺激正处于一个转折点，其临床证据不断扩大，并在慢性疼痛治疗中的应用日益增加，”Amzak Health合伙人安东尼·纳塔莱博士表示。“艾登和Nervonik团队开发了一个高度差异化的技术平台，我们相信这有潜力显著改善患者的体验，并且他们非常有能力抓住这一机遇。”

We are excited to lead this financing and to support the company through its next phase of growth.'.

我们很高兴主导这次融资，并支持公司进入下一个成长阶段。

About Nervonik

关于Nervonik

Nervonik, Inc. is a medical device company focused on developing neuromodulation technologies. The company's platform integrates stimulation and sensing to enable precision therapies for chronic pain and other neurological conditions. Nervonik is headquartered in Los Angeles, California.

Nervonik公司是一家专注于开发神经调节技术的医疗器械公司。该公司平台整合了刺激与传感功能，为慢性疼痛及其他神经系统疾病提供精准治疗。Nervonik总部位于美国加利福尼亚州洛杉矶。

SOURCE Nervonik Inc.

来源：Nervonik Inc.

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示